Oncology - Medicine.net

Report: Cancer deaths continue downward trend, modest improvements in survival for pancreatic cancer

byNational Cancer InstituteAge-standardized, delay-adjusted overall cancer incidence rates (2014–2018) and age-standardized overall cancer death rates (2015–2019) are illustrated for all cancer

Updated on: December 19,2023

12

Report: Cancer deaths continue downward trend, modest improvements in survival for pancreatic cancer

byNational Cancer InstituteAge-standardized, delay-adjusted overall cancer incidence rates (2014–2018) and age-standardized overall cancer death rates (2015–2019) are illustrated for all cancer

Updated on:December 19,2023

12

Exploring the links between diet and cancer

Omer Yilmaz’s work on how diet influences intestinal stem cells could lead to new ways to treat or prevent gastrointestinal cancers.Anne Trafton|MIT News OfficePublication Date:May 25, 202

Updated on: October 11,2023

130

Exploring the links between diet and cancer

Omer Yilmaz’s work on how diet influences intestinal stem cells could lead to new ways to treat or prevent gastrointestinal cancers.Anne Trafton|MIT News OfficePublication Date:May 25, 202

Updated on:October 11,2023

130

How Often Can You Donate Blood?

How Often Can You Donate Blood?ByLana BarhumPublished on June 14, 2023Medically reviewed byAnthony Pearson, MDThere are four ways todonate blood—whole blood, Power Red, p

Updated on: March 17,2024

0

How Often Can You Donate Blood?

How Often Can You Donate Blood?ByLana BarhumPublished on June 14, 2023Medically reviewed byAnthony Pearson, MDThere are four ways todonate blood—whole blood, Power Red, p

Updated on:March 17,2024

0

Imaging technique can observe specialized cancer treatment in breast cancer models

byJohns Hopkins University School of MedicineCredit: Unsplash/CC0 Public DomainFor nearly a century, scientific evidence has shown that the use of specific bacteria to target cancer tumors and t

Updated on: October 31,2023

7

Imaging technique can observe specialized cancer treatment in breast cancer models

byJohns Hopkins University School of MedicineCredit: Unsplash/CC0 Public DomainFor nearly a century, scientific evidence has shown that the use of specific bacteria to target cancer tumors and t

Updated on:October 31,2023

7

Scientists unveil chemotherapy resistance mechanism related to p53 mutation

by Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem (INBEB)Comparison between the response of tumoral cells to chemotherapy with no mutation of p53 (upper cells) and of mu

Updated on: December 20,2023

11

Scientists unveil chemotherapy resistance mechanism related to p53 mutation

by Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem (INBEB)Comparison between the response of tumoral cells to chemotherapy with no mutation of p53 (upper cells) and of mu

Updated on:December 20,2023

11

Cevidoplenib Elicits Platelet Responses in Persistent or Chronic Immune Thrombocytopenia

June 11, 2023Chris RyanThe novel SYK inhibitor cevidoplenib dosed at 400 mg twice per day led to robust platelet responses in patients with persistent or chronic primary immune thrombocytopenia who di

Updated on: October 24,2023

27

Cevidoplenib Elicits Platelet Responses in Persistent or Chronic Immune Thrombocytopenia

June 11, 2023Chris RyanThe novel SYK inhibitor cevidoplenib dosed at 400 mg twice per day led to robust platelet responses in patients with persistent or chronic primary immune thrombocytopenia who di

Updated on:October 24,2023

27

Progression-free survival increased with zanubrutinib in leukemia

by Elana Gotkine HealthDay ReporterProgression-free survival is significantly longer with zanubrutinib than ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or s

Updated on: December 19,2023

12

Progression-free survival increased with zanubrutinib in leukemia

by Elana Gotkine HealthDay ReporterProgression-free survival is significantly longer with zanubrutinib than ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or s

Updated on:December 19,2023

12

Biologists identify key step in lung cancer evolution

Blocking the transition to a more aggressive state could offer a new treatment strategy.Anne Trafton|MIT News OfficePublication Date:May 10, 2017 PRESS INQUIRIESCaption:MIT researche

Updated on: October 11,2023

66

Biologists identify key step in lung cancer evolution

Blocking the transition to a more aggressive state could offer a new treatment strategy.Anne Trafton|MIT News OfficePublication Date:May 10, 2017 PRESS INQUIRIESCaption:MIT researche

Updated on:October 11,2023

66

Novel tool helps differentiate between cancerous and healthy cells for AML

Spanish scientists have developed a new method to identify between cancerous and healthy cells for cases of acute myeloid leukaemia (AML).Researchers from Centre for Genomic Regulation (CRG), Spain, h

Updated on: October 31,2023

19

Novel tool helps differentiate between cancerous and healthy cells for AML

Spanish scientists have developed a new method to identify between cancerous and healthy cells for cases of acute myeloid leukaemia (AML).Researchers from Centre for Genomic Regulation (CRG), Spain, h

Updated on:October 31,2023

19

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

September 30, 2023Courtney FlahertyPatients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class

Updated on: October 10,2023

265

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

September 30, 2023Courtney FlahertyPatients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class

Updated on:October 10,2023

265

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

September 20, 2023Ashling WahnerEarly lung-specific response to atezolizumab plus bevacizumab was associated with longer overall survival in patients with hepatocellular carcinoma with pulmonary metas